Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of ALVAC-HIV and Adjuvanted Clade C Env Protein in Healthy Adults
NCT03122223Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2018
- Primary completion
- Jul 2020
- Modality
- Prophylactic Vaccines, Viral Vectors, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of ALVAC-HIV and bivalent subtype C gp120/MF59 in human immunodeficiency virus infection (HIV) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Reporting Local Reactogenicity Signs and Symptoms, Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms and 7 more. Started Jan 2018; status: completed.
02
Drugs
ALVAC-HIVbivalent subtype C gp120/MF59
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03122223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03122223.